PZ Cormay

PZ Cormay Acquisitions (Net)

The Acquisitions (Net) of PZ Cormay (CRM.WA) as of Nov 2, 2026 is 4.71 M PLN. In the previous year, Acquisitions (Net) was 11.15 M PLN — a change of -57.79% (lower).

Acquisitions (Net)

4.71 MPLN

YoY

-57.79%

Last updated:

Acquisitions (Net) of PZ Cormay is 2024 4.71 M PLN. Acquisitions (Net) of PZ Cormay was 2023 11.15 M PLN. It decreases by -57.79% lower compared to the previous year.

The PZ Cormay Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2017
4.31 M PLN
Jan 1, 2018
2.70 M PLN
Jan 1, 2019
30.52 M PLN
Jan 1, 2020
4.82 M PLN
Jan 1, 2021
2.02 M PLN
Jan 1, 2022
17.40 M PLN
Jan 1, 2023
11.15 M PLN
Jan 1, 2024
4.71 M PLN
The PZ Cormay Acquisitions (Net) history
YEARAcquisitions (Net)YoY
4.71 MPLN-57.79%
11.15 MPLN-35.91%
17.40 MPLN+760.73%
2.02 MPLN-58.02%
4.82 MPLN-84.22%
30.52 MPLN+1,028.66%
2.70 MPLN-37.26%
4.31 MPLN+223.09%
1.33 MPLN-126.38%
-5.06 MPLN-72.82%
-18.60 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PZ Cormay Stock analysis

What does PZ Cormay do? PZ Cormay SA manufactures diagnostic reagents and laboratory equipment, offering products like biochemical rapid tests, vacuette tubes, and devices including ACCENT-300, ACCENT-200, PRESTIGE 24i, LIVIA analyzers, MYTHIC 18 hematology analyzers, and IChem 100 urinalysis apparatus. The company serves clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation, and specific protein recognition segments. Its products are distributed through Orphee SA, which acquired 100% stake in TT Management Sp z o o on September 1, 2014, to transfer Cormay group's production and distribution activities. Orphee SA, now holding full control of Cormay's operations, manages the distribution of PZ Cormay SA's diagnostic reagents and laboratory equipment. The firm's revenue comes from selling biochemical analyzers, hematology analyzers, and related products to healthcare facilities and laboratories. PZ Cormay SA's product portfolio includes drugs, biochemical rapid tests, and devices such as vacuette tubes, targeting clinical and diagnostic markets with a focus on specialized equipment for medical analysis. The company's revenue streams are derived from the sale of its analytical devices and reagents, with Orphee SA handling the distribution after the 2014 restructuring. PZ Cormay SA's products are used in clinical chemistry, hematology, and other diagnostic segments, with specific equipment like the ACCENT-300 and MYTHIC 18 being key offerings. The restructuring plan transferred production and distribution to Orphee SA, enabling streamlined operations and market access. PZ Cormay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PZ Cormay stock

Acquisitions (Net) of PZ Cormay is 4.71 M PLN in 2024.

Acquisitions (Net) of PZ Cormay changed from 11.15 M PLN to 4.71 M PLN, representing a -57.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) PZ Cormay since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s PZ Cormay historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PZ Cormay

All Key Metrics — PZ Cormay